Prognostic and predictive factors and genetic analysis of early breast cancer

Clinical and Translational Oncology

Volumn 11, Issue 10, 2009, Pages 634-642

  Martín, Miguel ^a   Palacios, Fernando González ^b   Cortés, Javier ^c   De La Haba, Juan ^d   Schneider, José ^e  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Breast cancer; Genetic profi le; Microarrays; Predictive factor; Prognostic factor

Indexed keywords

TUMOR MARKER;

BREAST TUMOR; CANCER STAGING; FEMALE; GENETICS; HUMAN; METABOLISM; PROGNOSIS; REVIEW; TUMOR RECURRENCE;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 75349104487     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-009-0418-7     Document Type: Conference Paper

References (59)

1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
2. Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569-1583
3. Brenton JD, Carey LA, Ahmed AA et al (2005) Molecular classifi cation and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23:7350-7360
4. (1991) NIH consensus conference. Treatment of early-stage breast cancer. JAMA 265:391-395
5. Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181-187
6. Fisher B, Dignam J, Tan-Chiu E et al (2001) Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 93:112-120
7. Moatamed NA, Apple SK (2006) Extensive sampling changes T-staging of infi ltrating lobular carcinoma of breast: A comparative study of gross versus microscopic tumor sizes. Breast J 12:511-517
8. Perry N, Broeders M, de Wolf C et al (eds) (2006) European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis, 4th Edn. European Communities, Luxembourg
9. Pritt B, Weaver DL (2005) Accurate determination of breast cancer size: the role of histopathology and imaging. Curr Diag Pathol 11435-11442
10. Russo J, Frederick J, Ownby HE et al (1987) Predictors of recurrence and survival of patients with breast cancer. Am J Clin Pathol 88:123-131
11. Fisher ER, Anderson S, Redmond C, Fisher B (1993) Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 71:2507-2514
12. Saez RA, McGuire WL, Clark GM (1989) Prognostic factors in breast cancer. Semin Surg Oncol 5:102-110
13. Cserni G, Amendoeira I, Apostolikas N et al (2004) Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Tathology. J Clin Pathol 57:695-701
14. Turner RR, Weaver DL, Cserni G et al (2008) Nodal stage classifi cation for breast carcinoma: Improving interobserver reproducibility through standardized histologic criteria and imaged-based training. J Clin Oncol 26:258-263
15. European Working Group for Breast Screening Pathology. Cserni G, Amendoeira I, Apostolikas N et al (2003) Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer 39:1654-1667
16. Nasser IA, Lee AK, Bosari S et al (1993) Occult axillary lymph node metastases in "node-negative" breast carcinoma. Hum Pathol 24:950-957
17. Hainsworth PJ, Tjandra JJ, Stillwell RG et al (1993) Detection and signifi cance of occult metastases in node-negative breast cancer. Br J Surg 80:459-463
18. McGuckin MA, Cummings MC, Walsh MD et al (1996) Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer 73:88-95
19. de Boer M, van Deurzen CH, van Dijck JA et al (2008) Micrometastases and isolated tumor cells: relevant and robust or rubbish? (MIRROR): preliminary results of the MIRROR study from the Dutch Breast Cancer Trialists' Group (BOOG). Program and abstracts of the 31st Annual San Antonio Breast Cancer Symposium, December 10-14, San Antonio, TX, Abstract 23
20. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19:403-410
21. Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359-377
22. Rakha EA, El-Sayed ME, Lee AH et al (2008) Prognostic signifi cance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26:3153-3158
23. Harris GC, Denley HE, Pinder SE et al (2003) Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. Am J Surg Pathol 27:11-15
24. Sotiriou C, Wirapati P, Loi S et al (2006) Gene expression profi ling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262-272
25. Lee AHS, Pinder SE, Macmillan RD et al (2006) Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer 42:357-362
26. Mohsin SK, Bardou VJ, Arpino G et al (2003) Prognostic and predictive factors in breast cancer: an evidence-based medicine approach. In: Nabholtz JM, Tonkin K, Reese DM et al (eds) Breast cancer management, 2nd Edn. Lippincott Williams & Wilkins, Hagerstown, MD, pp 391-410
27. Wenger CR, Beardslee S, Owens MA et al (1993) DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 28:9-20
28. Robbins P, Pinder S, de Klerk N et al (1995) Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 26:873-879
29. Rhodes A, Jasani B, Balaton AJ et al (2001) Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe: documentation of poor reliability and identifi cation of insuffi cient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 115:44-58
30. Goldstein NS, Ferkowicz M, Odish E et al (2003) Minimun formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120:86-92
31. Schnitt SJ (2006) Estrogen receptor testing of breast cancer in current clinical practice: what's the question? J Clin Oncol 24:1797-1799
32. Ross JS, Symmans WF, Pusztai L et al (2007) Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. Clin Cancer Res 13:2831-2835
33. Kroman N, Jensen MB, Wohlfahrt J et al (2000) Factors infl uencing the effect of age on prognosis in breast cancer: population based study. BMJ 320:474-478
34. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplifi cation of the HER2/neu oncogene. Science 235:177-182
35. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
36. Palacios J, Andreu X, Calasanz MJ et al (2009) Guidelines for HER2 testing in breast cancer. A national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Rev Esp Patología 42:3-16
37. Wolff AC, Hammond EH, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145
38. Davis BW, Gelber R, Goldhirsch A et al (1985) Prognostic signifi cance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol 16:1212-1218
39. de Mascarel I, Bonichon F, Durand M et al (1998) Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer 34:58-65
40. Eppenberger U, Kueng W, Schlaeppi JM et al (1998) Markers of tumor angiogenesis and proteolysis independently defi ne high-and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 16:3129-3136
41. Foekens JA, Peters HA, Look MP et al (2000) The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60:636-643
42. Harbeck N, Thomssen C, Berger U et al (1999) Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following fi rst relapse. Breast Cancer Res Treat 54:147-157
43. Prechtl A, Harbeck N, Thomssen C et al (2000) Tumor-biological factors uPA and PAI-1 as stratifi cation criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer. Int J Biol Markers 15:73-78
44. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumors. Nature 406:747-752
45. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874
46. van't Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profi ling predicts clinical outcome of breast cancer. Nature 415:530-536
47. van de Vijver MJ, van't Veer LJ, Dai H et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009
48. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, nodenegative patients. N Engl J Med 351:2817-2226
49. Buyse M, Loi S, van't Veer L et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183-1192
50. de Snoo FA, Knauer M, Bender RA et al (2009) Outcome prediction by the 70-gene profile in the context of the National Comprehensive Cancer Network (NCCN) guidelines. J Clin Oncol 15[Suppl]:abstr 535
51. Bender RA, Knauer M, Rutgers EJ et al (2009) The 70-gene profile and chemotherapy benefi t in 1,600 breast cancer patients. J Clin Oncol 27[Suppl]:abstr 512
52. Bogaerts J, Cardoso F, Buyse M et al (2006) Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 3:540-551
53. Sparano JA (2006) TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347-350
54. Wirapati P, Sotiriou C, Kunkel S et al (2008) Meta-analysis of gene expression profi les in breast cancer: toward a unifi ed understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10:R65
55. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790-800
56. Hornberger J, Cosler LE, Lyman GH (2005) Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 11:313-324
57. Tong KB, Chen E, Brink G (2009) Cost-effectiveness of targeting chemotherapy with the 70-gene prognostic signature in early-stage breast cancer (ESBC) patients. J Clin Oncol 27[Suppl]:abstr 6570
58. Straver ME, Glas AM, Hannemann J et al (2009) The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (in press)
59. Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 20:1319-1329